This transcript has been edited for clarity. Vallerie McLaughlin, MD: Hello, and welcome to this podcast series. I'm Dr Vallerie McLaughlin, the Kim A. Eagle Endowed Professor of Cardiovascular ...

Researchers describe the underlying signaling pathway that results in pulmonary arterial hypertension and a novel monoclonal antibody therapy that blocks the abnormal blood vessel formation ...

Group 1 pulmonary hypertension (or pulmonary arterial hypertension) is a rare, highly complex, and progressive disorder that is incurable and ultimately can lead to premature death. PAH causes ...

With a $125 million series B financing round, Diagonal Therapeutics has made a vertical move to advance its first-in-class ...

Pulmonary embolism (PE) and pulmonary fibrosis (PF) are potential causes of pulmonary hypertension. A ventilation-perfusion (V/Q) scan is the most useful test for PE, 4 and a contrast CT scan of the ...

Winrevair, also known as sotatercept-csrk, is a medicine used to treat pulmonary arterial hypertension (PAH), which causes high blood pressure in the arteries that go from your heart to your lungs.

Please provide your email address to receive an email when new articles are posted on . Among pediatric patients in the Pediatric Pulmonary Hypertension Network, nearly half had group 3 disease, ...

A 40-year-old woman who was once accustomed to frequent travel suddenly found herself struggling to breathe after just a few ...